Illumina, Inc. Fiscal 2014 Form 10-K Summary
Business context and reporting period
Illumina is a global provider of sequencing- and array-based systems, consumables, services, and genomic informatics solutions used in research, clinical, reproductive-health, oncology, agricultural, pharmaceutical, and diagnostic applications. The filing covers the 52-week fiscal year ended December 28, 2014; the referenced fourth quarter ended December 28, 2014 and also comprised 13 weeks. Illumina reported one operating and reportable segment.
International shipments represented 49% of revenue, compared with 50% in fiscal 2013. The company had more than 3,700 employees and approximately $540 million of backlog at year-end, including approximately $130 million related to the Genomics England sequencing-services project.
Key financial metrics
| Metric | Fiscal 2014 | Fiscal 2013 | Change |
|---|---|---|---|
| Total revenue | $1.861 billion | $1.421 billion | Up 31% |
| Product revenue | $1.620 billion | $1.265 billion | Up 28% |
| Service and other revenue | $241.8 million | $156.5 million | Up 55% |
| Gross profit | $1.298 billion | $911.9 million | Up 42% |
| Gross margin | 69.7% | 64.2% | Up 5.5 percentage points |
| Income from operations | $514.7 million | $134.1 million | Up $380.6 million |
| Net income | $353.4 million | $125.3 million | Up 182% |
| Diluted earnings per share | $2.37 | $0.90 | Up 163% |
| Net cash from operating activities | $501.3 million | $386.4 million | Up 30% |
Fourth-quarter revenue was $512.4 million, gross profit was $384.9 million, and net income was $153.3 million, or $1.03 diluted earnings per share. The filing does not provide a separately stated fourth-quarter gross margin or operating income.
Consumables revenue increased 18% to $1.041 billion, instrument revenue increased 51% to $562.2 million, and service and other revenue increased 55% to $241.8 million. Consumables represented 56% of total revenue and instruments represented 30%.
Research and development expense rose 40% to $388.1 million, while selling, general and administrative expense rose 22% to $466.3 million. Share-based compensation expense was $152.6 million before tax. The effective tax rate was 21.3%, compared with the 35% U.S. federal statutory rate, primarily because of lower-tax foreign earnings and tax credits.
Liquidity, cash flow, debt, and commitments
- Cash and cash equivalents were $636.2 million and short-term investments were $702.2 million at year-end, for combined liquidity of approximately $1.338 billion.
- Cash flow from operations was $501.3 million. Capital expenditures were $106.0 million, and cash used in investing activities was $406.6 million.
- Net cash used in financing activities was $166.7 million, reflecting debt refinancing, share repurchases, and other financing items. Cash and cash equivalents declined by $75.5 million during the year.
- Outstanding convertible-note principal totaled approximately $1.470 billion: $320.0 million due in 2016, $632.5 million due in 2019, and $517.5 million due in 2021. The 2016 notes were classified as current because they were convertible through March 31, 2015.
- Illumina issued $1.150 billion of 2019 and 2021 convertible notes and used proceeds plus cash on hand to repurchase $600.0 million principal amount of 2016 notes. The transaction generated a $31.4 million loss on debt extinguishment.
- The company repurchased approximately 1.5 million shares for $237.2 million during fiscal 2014. Approximately $130.4 million remained available under repurchase authorizations at year-end.
- Contractual obligations totaled $2.242 billion, excluding $123.0 million of contingent acquisition consideration and $52.1 million of uncertain tax positions. A facility lease signed December 30, 2014 is expected to add approximately $204.0 million of rent over its initial term beginning in 2017.
- Management stated that cash, investments, and expected operating cash flow were sufficient to fund near-term operating and capital requirements for at least 12 months.
Material changes versus the prior comparable period
- Revenue growth accelerated, led by HiSeq X Ten and NextSeq instrument shipments, growth in the installed base, higher sequencing consumables demand, sequencing services, and extended service contracts.
- Gross margin improved materially because of higher sequencing-instrument margins, manufacturing efficiencies, and a $10.4 million reversal of cost of sales associated with the Syntrix settlement. Fiscal 2013 had included a $25.2 million impairment charge related to discontinued Eco and NuPCR product lines.
- Operating results benefited from an $82.1 million legal-contingency gain related to Syntrix, compared with a $115.4 million legal-contingency charge in 2013. Fiscal 2014 also included a $48.8 million research and development charge from the Sequenom settlement and patent-pooling arrangements.
- Service and other revenue increased as a percentage of total revenue to 13.0% from 11.0%, while product revenue declined to 87.0% from 89.0%.
- Operating cash flow increased to $501.3 million from $386.4 million, although working-capital investment increased, including higher accounts receivable and inventory.
- Short-term investments increased to $702.2 million from $454.0 million, while cash and cash equivalents decreased to $636.2 million from $711.6 million.
Guidance, outlook, commentary, risks, and unusual items
Management expected revenue to continue increasing in 2015 and expected research and development expense to rise to support product development and business growth. The company also planned to expand manufacturing, sales, distribution, service capacity, facilities, and global business systems.
Unusual fiscal 2014 items included the Syntrix settlement gain, the Sequenom settlement charge, the debt-extinguishment loss, share-based compensation, and acquisition-related fair-value adjustments. The filing states that no significant off-balance-sheet arrangements existed.
- Key business risks include rapid technological change, intense competition, product-transition and launch risk, manufacturing and supply-chain constraints, reliance on single-source suppliers, and the possibility of product defects or recalls.
- Clinical and diagnostic growth depends on uncertain FDA and international regulatory approvals, evolving regulation of laboratory-developed tests, and third-party reimbursement decisions.
- International operations expose the company to currency, geopolitical, tax, collection, trade, and regulatory risks. The company recorded a $5.4 million net currency-exchange loss in fiscal 2014.
- Research demand may be affected by reductions or delays in government, academic, and pharmaceutical research funding.
- Pending litigation and claims remain inherently uncertain. Management stated that ultimate losses could exceed recorded accruals and potentially materially affect results or cash flow.
- The FDA issued draft guidance in October 2014 concerning potential regulation of laboratory-developed tests; the company could not predict the final framework or its effect on the business.
- The company was implementing new enterprise resource planning systems, creating potential execution, data, service, and margin-management risks.
Ernst & Young issued unqualified opinions on the consolidated financial statements and internal control over financial reporting. Management concluded that disclosure controls and internal controls were effective as of December 28, 2014.
Important facts for investors to verify
- Determine how much of fiscal 2014 earnings growth was recurring versus generated by the Syntrix settlement, other legal items, tax benefits, investment gains, and debt-related accounting effects.
- Assess the sustainability of the 69.7% gross margin as product mix shifts between instruments, consumables, services, and newer platforms.
- Monitor conversion, refinancing, and potential cash-settlement requirements for the $320.0 million of 2016 convertible notes and the later-dated notes.
- Evaluate whether backlog, particularly the Genomics England project, converts to revenue and cash flow on the expected timetable.
- Track regulatory developments affecting MiSeqDx, NIPT products, laboratory-developed tests, and future diagnostic offerings, together with reimbursement trends.
- Review exposure to patent disputes, contingent acquisition payments, uncertain tax positions, foreign earnings held offshore, and single-source suppliers.
- Verify the effect of continued research and development, sales infrastructure, manufacturing expansion, acquisitions, leases, and share-based compensation on future margins and free cash flow.